Healthcare policy expert Indu Bhushan. File | Photo Credit: The Hindu Healthcare policy expert and former CEO of the National Health Authority Indu Bhushan, in an exclusive interview with The Hindu, examined whether the National Pharmaceutical Pricing Authority’s (NPPA) recent decision to cap trade margins on 137 anti-cancer medicines will translate into meaningful savings for patients.Drawing on his experience implementing the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), he highlights the need for pricing transparency, regulatory oversight and sustainable healthcare financing. Published - October 29, 2026 06:57 pm IST
Financial protection for patients cannot be achieved through a single intervention: former National Health Authority CEO
Full Article
Original Source
Read the full article at Thehindu →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.